New Antitumour Compounds for Colon Cancer

This technology offer comprises a portfolio of 2 to 3 novel extracts obtained from marine organisms. These compounds have been selected for their ability to inhibit the growth of colon tumour cell lines, demonstrating greater efficacy in in vitro assays.

We have 2 to 3 extracts of marine origin that demonstrate activity in colon cancer cell models and whose composition has been partially characterised.

There are several advantages, which can be summarised as follows:

• More than 15 years of experience in research into new antitumour agents and more than 25 years of research into the use of natural compounds.
• Extracts already characterised in in vitro models, with high development potential.

In vitro validation. The extracts have already demonstrated their efficacy in laboratory cell models. The technology is ready for the lead optimisation stage and progression to in vivo models, in collaboration with biotechnology or pharmaceutical companies.

• Pharmaceutical industry (oncology departments).
• Biotechnology companies specialising in drug discovery.
• Biomedical and oncology research centres.

Enrique Barrajón Catalán – Institute for Research, Development and Innovation in Healthcare Biotechnology of Elche (IDIBE)